利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

26 条记录 (耗时 0.052 秒)

    Human monoclonal antibodies against CD30
    1.
    发明授权
    Human monoclonal antibodies against CD30 有权
    针对CD30的人单克隆抗体

    公开(公告)号：US08088377B2

    公开(公告)日：2012-01-03

    申请号：US12080817

    申请日：2008-04-04

    申请人： Tibor Keler ,  Robert Graziano ,  John Treml ,  Yashwant M. Deo

    发明人： Tibor Keler ,  Robert Graziano ,  John Treml ,  Yashwant M. Deo

    IPC分类号： A61K39/395 ,  G01N33/53 ,  C07K16/46 ,  C07K16/28

    CPC分类号： C07K16/2878 ,  A01K2217/075 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/73 ,  Y02A50/412

    摘要： Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

    摘要翻译： 公开了与CD30结合的分离的人单克隆抗体（例如人CD30）。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的非人转基因动物，例如转基因小鼠中产生。 还公开了人抗体（例如双特异性抗体和免疫偶联物）的衍生物，包含人抗体，非人转基因动物和产生人抗体的杂交瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

    Human monoclonal antibodies against CD30
    2.
    发明授权
    Human monoclonal antibodies against CD30 有权
    针对CD30的人单克隆抗体

    公开(公告)号：US07387776B2

    公开(公告)日：2008-06-17

    申请号：US10338366

    申请日：2003-01-07

    申请人： Tibor Keler ,  Robert Graziano ,  John Treml ,  Yashwant M. Deo

    发明人： Tibor Keler ,  Robert Graziano ,  John Treml ,  Yashwant M. Deo

    IPC分类号： A61K39/395 ,  C07K16/46 ,  C07K16/24 ,  C07K16/00

    CPC分类号： C07K16/2878 ,  A01K2217/075 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/73 ,  Y02A50/412

    摘要： Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

    摘要翻译： 公开了与CD30结合的分离的人单克隆抗体（例如人CD30）。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的非人转基因动物，例如转基因小鼠中产生。 还公开了人抗体（例如双特异性抗体和免疫偶联物）的衍生物，包含人抗体，非人转基因动物和产生人抗体的杂交瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

    Human monoclonal antibodies to dendritic cells
    5.
    发明授权
    Human monoclonal antibodies to dendritic cells 有权
    人类对树突状细胞的单克隆抗体

    公开(公告)号：US07563876B2

    公开(公告)日：2009-07-21

    申请号：US09851614

    申请日：2001-05-08

    申请人： Yashwant M. Deo ,  Tibor Keler ,  John Treml

    发明人： Yashwant M. Deo ,  Tibor Keler ,  John Treml

    IPC分类号： C12P21/08

    CPC分类号： A61K39/0011 ,  A61K47/6849 ,  A61K2039/505 ,  A61K2039/515 ,  A61K2039/6056 ,  C07K14/705 ,  C07K16/28 ,  C07K16/46 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/622 ,  C07K2317/77 ,  C07K2319/00 ,  G01N33/564

    摘要： Isolated human monoclonal antibodies and antigen-binding portions thereof which specifically bind to dendritic cells are disclosed. Also disclosed are bispecifics, immunotoxins and antigen conjugates which include the antibodies or antibody portions. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

    摘要翻译： 公开了与树突状细胞特异性结合的分离的人单克隆抗体及其抗原结合部分。 还公开了包括抗体或抗体部分的双特异性，免疫毒素和抗原缀合物。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的非人转基因动物，例如转基因小鼠中产生。 还公开了包含人抗体，非人转基因动物和产生人抗体的杂交瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

    Therapeutic compounds comprised of anti-FC receptor binding agents
    9.
    发明授权
    Therapeutic compounds comprised of anti-FC receptor binding agents 有权
    由抗FC受体结合剂组成的治疗化合物

    公开(公告)号：US06365161B1

    公开(公告)日：2002-04-02

    申请号：US09364088

    申请日：1999-07-30

    申请人： Yashwant M. Deo ,  Joel Goldstein ,  Robert Graziano ,  Tibor Keler

    发明人： Yashwant M. Deo ,  Joel Goldstein ,  Robert Graziano ,  Tibor Keler

    IPC分类号： A61K39395

    CPC分类号： C07K16/3007 ,  A61K38/00 ,  C07K14/33 ,  C07K14/485 ,  C07K16/283 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2319/00

    摘要： Multispecific molecules which target immune cells are disclosed. The molecules are “multispecific” because they bind to multiple (two or more), distinct targets, one of which is a molecule on the surface of an immune cell. Multispecific molecules of the invention include molecules comprised of at least one portion which binds to a molecule on an effector cell, such as an Fc receptor, and at least one portion (e.g., two, three, four or more portions) which binds to a different target, such as an antigen on a tumor cell or a pathogen. Multispecific molecules of the invention also include antigen “multimer complexes” comprised of multiple (i.e., two or more) portions which bind to a molecule on an antigen presenting cell (APC), such as an Fc receptor, linked to one or more antigens. These multimer complexes target antigens, such as self-antigens, to APCs to induce and/or enhance internalization (endocytosis), processing and/or presentation of the antigen by the APC. Therefore, these molecules can be used to induce or enhance an immune response either in vivo or in vitro against a normally non-immunogenic protein, such as a self-antigen.

    摘要翻译： 公开了靶向免疫细胞的多特异性分子。 分子是“多特异性的”，因为它们结合多个（两个或多个）不同的靶，其中之一是免疫细胞表面上的分子。 本发明的多特异性分子包括由至少一部分结合到效应细胞上的分子（例如Fc受体）和至少一部分（例如，两个，三个，四个或更多个部分）结合的分子 不同的靶，例如肿瘤细胞或病原体上的抗原。 本发明的多特异性分子还包括与多个（即两个或更多个）部分结合的抗原“多聚体复合物”，其与一个或多个抗原连接的抗原呈递细胞（APC）如Fc受体上的分子结合。 这些多聚体复合物将抗原（例如自身抗原）靶向APC以诱导和/或增强APC的内化（内吞作用），加工和/或呈递抗原。 因此，这些分子可以用于在体内或体外诱导或增强针对正常非免疫原性蛋白（例如自身抗原）的免疫应答。